Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.70 EUR
Change Today -0.001 / -0.14%
Volume 237.2K
TIG On Other Exchanges
EN Brussels
As of 9:42 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

tigenix nv (TIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - €0.84
52 Week Low
10/16/14 - €0.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIGENIX NV (TIG)

Related News

No related news articles were found.

tigenix nv (TIG) Related Businessweek News

No Related Businessweek News Found

tigenix nv (TIG) Details

TiGenix NV, a biomedical company, develops and commercializes cell therapy products. The company’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. Its lead product, ChondroCelect, is a cell-based product that is used for cartilage repair in the knee. The company is also involved in developing Cx601, which is in Phase III clinical trial for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease; Cx611, an allogeneic eASC product candidate, which has completed a Phase IIa clinical trial for the treatment of rheumatoid arthritis; and Cx621, an allogeneic eASC product candidate that has completed a Phase I trial for the treatment of autoimmune diseases through intra-lymphatic administration. The company has operations in Belgium, the Netherlands, the United Kingdom, and internationally. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

49 Employees
Last Reported Date: 03/27/15
Founded in 2000

tigenix nv (TIG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €433.6K
Compensation as of Fiscal Year 2013.

tigenix nv (TIG) Key Developments

TiGenix N.V. Proposes Modification to Articles of Association

TiGenix N.V. announced that it will propose modification to Article 27 of the articles of association, at its annual and the extraordinary shareholders' meeting to be held on April 20, 2015.

TiGenix N.V. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

TiGenix N.V. reported consolidated earnings results for the year ended December 31, 2014. For the period, the company reported total revenue of EUR 6,286,000 compared to EUR 883,000 a year ago. Operating loss was EUR 12,563,000 compared to EUR 14,789,000 a year ago. Loss before tax was EUR 12,313,000 compared to EUR 15,179,000 a year ago. Loss for the period from continuing operations was EUR 11,386,000 compared to EUR 15,120,000 a year ago. Loss for the period was EUR 12,990,000 compared to EUR 18,390,000 a year ago. Basic and diluted loss per share was EUR 0.08 compared to EUR 0.16 a year ago. Basic and diluted loss per share from continuing operations was EUR 0.07 compared to EUR 0.13 a year ago.

TiGenix N.V. Completes Treatment in Phase I Sepsis Challenge Trial with Cx611

TiGenix NV announced that it has completed the treatment of 32 subjects in its Phase I trial of Cx611 in a sepsis challenge model. No serious adverse events have been reported. Full results will be announced in the second quarter of 2015. Cx611 is an intravenously-administered product of allogeneic expanded adipose-derived stem cells (eASCs). Its efficacy in significantly reducing mortality has been demonstrated in several animal models of sepsis through a combination of reduced inflammation, production of anti-microbial effectors, and increased phagocytosis. This trial, codenamed CELLULA, is designed to confirm the safety and demonstrate the anti-inflammatory effect of Cx611 on the sepsis-like clinical symptoms and immunological response elicited by an intravenous administration of a bacterial endotoxin (lipopolysaccharide) in healthy volunteers. The trial is a placebo-controlled dose-ranging study (3 doses of Cx611) in 32 healthy male volunteers. It is being conducted in the Academic Medical Center of the University of Amsterdam in the Netherlands, which is a centre of excellence for such trials. No serious adverse events have been reported. Complete study results are expected in the second quarter of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIG:BB €0.70 EUR -0.001

TIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Vericel Corp $3.28 USD -0.0218
View Industry Companies

Industry Analysis


Industry Average

Valuation TIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIGENIX NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at